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Abstract
Background: Acute myeloid leukemia (AML) is commonly characterized by several chromosomal abnormalities
resulting in the formation of chimeric genes that play various roles in leukemogenesis. Translocations resulting in
the ETV6-ABL1 fusion gene are rare in AML and other hematologic malignancies with only thirty-two previously
reported cases in the literature, five of which were AML.
Findings: Herein, we report the case of a 73-year-old male with acute myeloid leukemia arising from MDS, negative
for PDGFRA and PDGFRB, positive for bone marrow eosinophilia, rash, and marked fluid retention, which improved
dramatically with imatinib therapy. Conventional cytogenetics revealed a t(3;9)(p25;q34), t(5;18)(q13;p11.2), and
additional material of unknown origin at 12p11.2 in 2 out of 10 metaphases analyzed. Interphase FISH studies showed
evidence of ETV6 (12p13) and ABL1 (9q34) rearrangements in 41.3 % and 5.7 % of the cells respectively. FISH studies on
previously G-banded metaphases showed colocalization of ABL1 and ETV6 signals to the short arm of chromosome 3
at 3p25 suggesting a possible ETV6-ABL1 fusion. Subtelomeric metaphase FISH studies also showed the presence of a
subtelomere 3p signal on the long arm of the derivative 9, and no subtelomere 3p signal on the derivative
chromosome 12.
Conclusions: These findings suggest a complex rearrangement involving an insertion of ETV6 into 3p25 followed by a
reciprocal translocation involving 3p25 and 9q34, resulting in a possible ETV6-ABL1 fusion. This case highlights the
importance of FISH to characterize complex rearrangements in myeloid malignancies, particularly those resulting in
clinically significant chimeric genes.
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Introduction
The ETV6-ABL1 fusion gene is uncommon in hemato-
logical malignancies, including chronic myeloid leukemia
(CML), acute myeloid leukemia (AML), and acute
lymphoblastic leukemia (ALL), and has been reported in
only thirty-two patients [1]. Six reported cases of hema-
tological malignancies bearing ETV6-ABL1 in the con-
text of complex rearrangements involving additional
translocation partners have been reported, resulting in
the translocation of the fusion gene to a third derivative
chromosome [2–7]. The rarity of this event is due in
part to the opposite transcriptional orientation of ETV6
and ABL1 relative to the centromere, which requires at
least three separate chromosomal breaks to form a func-
tional fusion gene [8]. The structure and function of the
ETV6-ABL1 oncoprotein is very similar to that of the
BCR-ABL1 protein with the ETV6 helix loop helix do-
main (HLH) deregulating the kinase activity of ABL1
leading to activation of a non-receptor tyrosine kinase
that initiates downstream pathways affecting growth
rate, cellular survival, and independence as well as trans-
forming capacity [1, 3]. Because of the common functional
activity with the BCR-ABL1 fusion protein, ETV6-ABL1
positive patients have been observed to respond to therapy
with tyrosine kinase inhibitors, albeit at varying degrees
and with high likelihood of relapse [1].
Herein, we present the case of a 73-year-old male di-
agnosed with acute myeloid leukemia. Cytogenetic ana-
lysis revealed a t(5;18) and a t(3;9), as well as additional
material of unknown origin on the short arm of chromo-
some 12. Additional interphase and metaphase FISH
studies revealed an insertion of ETV6 into 3p and trans-
location of ABL1 to the same locus on 3p, resulting in a
possible ETV6-ABL1 fusion gene. The patient responded
transiently to imatinib therapy, but eventually relapsed
and expired.
Case presentation
The patient was a 73-year-old male with acute myeloid
leukemia (AML) and hypereosinophilia, arising from
antecedent myelodysplastic syndrome (MDS). He was
initially found to have thrombocytopenia fifteen months
prior to transfer during a pre-surgical workup for sur-
gery to treat carpal tunnel syndrome. A bone marrow bi-
opsy performed six months later had findings consistent
with myelodysplastic syndrome with fewer than 5 %
blasts in the bone marrow. He subsequently received
three cycles of decitabine: the first dose was given in
February 2015, the second dose was given in May 2015,
and the third dose was given in July 2015. Eight months
after bone marrow biopsy, he presented to an outside
hospital with a fever and was found to have leukocytosis
with circulating blasts, and a repeat bone marrow biopsy
identified AML, possibly acute eosinophilic leukemia,
with 20 % blasts identified in the bone marrow. Broad-
spectrum antibiotics were started and the patient was
transferred to UCLA for escalation of care. Shortly after
transfer, he developed progressive renal failure requiring
dialysis. Persistent blasts were treated with azacytidine,
but he developed severe pancytopenia. In addition, eosino-
philia, rash and marked fluid retention led his clinical
team to consider therapy with imatinib, which promptly
led to resolution of those findings. A follow-up bone mar-
row aspiration and biopsy one month later identified a
hypercellular marrow showing marked eosinophilia with
increased atypical immature forms, markedly reduced
myeloid precursors other than the eosinophilic series in-
cluding increased atypical immature eosinophils, reduced
erythropoiesis and megakaryopoiesis, and increased blasts
(10-11 % of the marrow elements). The overall marrow
histology was consistent with acute myeloid leukemia pos-
sibly, acute myelocytic leukemia.
Material and methods
Conventional cytogenetics
Chromosome analysis was performed using standard
cytogenetic techniques on the bone marrow samples
from this patient. The karyotypes were prepared using
the Applied Imaging CytoVision software (Applied Im-
aging, Genetix, Santa Clara, CA) and described accord-
ing to the ISCN 2013 nomenclature [9].
FISH
Fluorescence in situ hybridization (FISH) was performed
on interphase nuclei using the Vysis BCR/ABL1/ASS1
Tri-color DF FISH Probe Kit, Vysis LSI BCR/ABL Dual
Color, Dual Fusion Probe Kit, and Vysis ETV6 Break
Apart FISH Probe Kit from Abbott Molecular (Des
Plaines, Illinois 60018) on interphase nuclei. Additionally,
metaphase FISH was performed with the TotelVysion 3p,
Spectrum Green, TotelVysion 3q Spectrum Orange




Conventional cytogenetics revealed a t(3;9)(p25;q34),
t(5;18)(q13;p11.2), and additional material of unknown
origin at 12p11.2 in 2 out of 10 metaphases analyzed.
The remaining 8 metaphases were cytogenetically nor-
mal (Fig. 1).
FISH
Interphase FISH studies confirmed a rearrangement in
41.3 % (124/300) of nuclei examined involving ETV6
using the Vysis ETV6 Break Apart FISH Probe Kit and a
rearrangement involving ABL1 in 5.7 % (17/300) nuclei
examined using Vysis BCR/ABL1/ASS1 Tri-color DF
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FISH Probe Kit. These findings were described as (Figs. 2
and 3):
nuc ish(ASS1x2,ABL1x3,BCRx2)[17/300]
nuc ish(ETV6x2)(5'ETV6 sep 3'ETV6x1)[124/300]
Metaphase FISH studies using the same probes on
previously G-banded metaphases showed colocalization
of ABL1 and ETV6 signals to the short arm of chromo-
some 3, suggesting the presence of an ETV6-ABL1 fu-
sion gene. Subtelomeric metaphase FISH studies also
showed the presence of a subtelomere 3p signal on the
derivative 9q, and no subtelomere 3p signals on the de-
rivative 12. In light of conventional cytogenetic findings,





This case highlights the formation of a potential ETV6-
ABL1 fusion gene as a result of a complex, three-way re-
arrangement. The conventional and molecular cytogenetic
Fig. 1 G-banded karyotype showing a three-way rearrangement involving 3, 9, and 12 as well as reciprocal translocation between chromosomes
5 and 18
Fig. 2 Interphase FISH showing ABL1 rearrangement (evidenced by
additional red ABL1 signal)
Fig. 3 Interphase FISH showing ETV6 rearrangement (evidenced by
split red and green ETV6 signals)
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findings in this case suggest an insertion of ETV6 in the
short arm of the derivative chromosome 3 followed by a
reciprocal translocation involving the same derivative
chromosome 3 and ABL1 (9q34), resulting in the potential
fusion gene. The breakpoint on chromosome 3 at which
the aforementioned rearrangements occurred - 3p25 -
harbors ANKRD28 (3p25.1), which has been implicated in
AML in the context of t(3;11)(p25;p15) involving NUP98
(11p15) [10]. In other studies, 3p25 was found to be the
most frequently deleted chromosomal band on 3p in
AML [11]. Given this information, the involvement of
3p25 in this three-way rearrangement may result in
deregulation of particular target genes relevant to
leukemogenesis in this region. The translocation that oc-
curred concomitant to the three-way rearrangement -
t(5;18)(q13;p11.2) - has not been observed in AML and
has not been associated with any clinical or hematopatho-
logic features.
In total, there have been thirty-two reported cases of
ETV6-ABL1 fusion gene in numerous hematologic ma-
lignancies including eleven cases of acute lymphoblastic
leukemia, five cases of acute myeloid leukemia, and six-
teen cases of myeloproliferative neoplasms (including
CML) (Table 1). The rarity of this chromosomal re-
arrangement is thought to be due in part to the opposite
transcriptional orientation of two genes relative to the
centromere, which requires at least three break-and-join
events for an in-frame fusion transcript to be formed.
The rearrangement is often not detected using conven-
tional cytogenetic techniques because of its cryptic na-
ture due to the similar G-banding pattern of the distal
long arm of chromosome 9 and the distal short arm of
chromosome 12 [12]. Additionally, it has been observed
that commercially available ABL1 FISH probes may not
detect aberrations in the gene in this context, suggesting
that the abnormality may remain undetected in a num-
ber of cases. In interphase cells, for example, the result-
ing ABL1 signal can be disproportionately small and can
potentially be considered as noise and disregarded [1].
Thus, the rarity of the ETV6-ABL1 fusion is not only
due to the multi-step mechanism required for its forma-
tion, but also because of technological limitations of
FISH probes and molecular cytogenetic analysis.
To date, five cases of AML bearing a possible ETV6-
ABL1 fusion have been reported (Table 1). Two of the
cases were designated M1, two were M6, and one was
not reported. One of the cases showed a straightforward
t(9;12)(q34;p13) with concurrent FISH studies showing
the 3’ ABL1 signal on the 12p, albeit in the context
of a complex karyotype [4]. Two of the cases showed
Fig. 4 Metaphase FISH showing localization of 5’ ETV6 red signal to
the short arm of the derivative chromosome 3. The derivative
chromosome 12 only shows the 3’ ETV6 green signal
Fig. 5 Metaphase FISH showing colocalization of ABL1 (red signal)
and 5’ ETV6 (red signal) signals to the short arm of chromosome 3
using the BCR/ABL1/ASS1 Tri-color DF FISH Probe Kit and ETV6 Break
Apart FISH Probe Kit
Fig. 6 Metaphase FISH showing localization of subtelomere 3p
signal on the derivative chromosome 9 and no subtelomeric 3
signals on the derivative chromosome 12
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Table 1 Reported cases of ETV6-ABL1 fusion in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myeloproliferative
neoplasm (MPN), including chronic myelogenous leukemia (CML)
Reference Age/Sex Karyotype FISH Transcript
Acute lymphoblastic leukemia (ALL)
[23] 22 mo/F N/A N/A Type A
[24] 4 yo/M 47,XXYc,del(6)(q15q23)[35]/47,XXYc[7] Intact ETV6 (5’ and 3’) on derivative 9 Type A and B
[25] 30 yo/M 45,XY,der(1)t(1;9)(q41;q?),der(9)t(9;13)(q?;q12.3),
del(9p21.1 ~ p23),-13,der(16)t(16;22)(p13.3;q11.2)
ABL1 signal on apparently normal chromosome 12 Type A and B
[26] 8 yo/F N/A N/A Type A and B




Normal signal patterns Type A and B
[7] 5 yo/M 46,XY[20] Normal signal patterns Type A and B
[7] 33 yo/F 46,XX,t(8;9;12)(p12;q34;p13)[22] ABL1 signal on 12p Type A and B
[13] 25 yo/F 46,XX,del(9)(p22),der(10)t(9;10)(q22; p15)[12]/
46,XX[8]
N/A Type A and B
[27] 58 yo/M 46,XY,t(9;12)(q34;p13)[2]/45,XY, −2,−14,+17[2]/
46,XY[16]
N/A Type A and B
[27] 49 yo/F 46,XY,t(9;12)(q34;p13)[10] N/A Type A and B
[12] 30 yo/F 47,XX,+5[19]/46,XX[1] Extra ETV6 and ABL1 signals in interphase nuclei Type A and B
Acute myeloid leukemia (AML)
[3] 81 yo/M t(9;12;14)(q34;p13;q22) in the context of
complex karyotype
ETV6 signal on derivative 14 with
concomitant deletion of other ETV6 allele
Type B
[4] 29 yo/F 46,XY,t(8;12)(p21;p13)[15] 5’ ETV6 and ABL1 signals on derivative 8 Type A
[4] 48 yo/F 46,XY,t(9;12)(q34;p13)[18/20]/
51,XY,+8,+9,t(9;12)(q34;p13),+12,+14,+17[2]
5’ ETV6 signal on derivative 9 Type B
[14] 38 yo/M 49,XY,+11,t(9;12)(q34;p1?),
+der(12)t(9;12),+19,der(22)t(1;22)(q21;q11)
ETV6-ABL1 fusion signals on 2 homologues
of chromosome 12
Type A and B
[13] 52 yo/M 46,XY[20] ABL1 signal on apparently normal
chromosome 12
Type B
Myeloproliferative neoplasm (MPN), including chronic myeloid leukemia (CML)
[28] 49 yo/M N/A N/A Type B
[2] 32 yo/M t(12;14)(p12;q11-13)[24]/46,XY[1] 5’ ETV6 on apparently normal chromosome 9 Type B
[24] 59 yo/M 46,XY,del(6)(p21),?t(9;12)(q34;p12)[16] 5’ ETV6 on derivative 9q Type A and B
[29] 44 yo/F 46,XX,t(9;12)(q34;p13)[16]/46,XX[4] 5’ ETV6 on derivative 9q N/A
[30] 53 yo/M 46,XY[20] Normal signal patterns Type A and B
[20] 36 yo/M 45,XY,-7,t(9;12)(q34;q13)[2]/
45,idem,t(12;13)(p12;q13)[10]/46,XY[13]
ABL1 signal on derivative 12 Type A
[6] 72 yo/M 46,XY,t(12;17) (p11.2;p11.2) ABL1 and ETV6 signals on derivative 17 Type B
[31] 65 yo/F 46,XX,t(5;9)(q13;q34) 3’ ABL1 on 12p Type B
[32] 57 yo/M 46,XY 3’ ABL1 on 12p N/A
[18] 24 yo/F 46,XX ETV6 signal on apparently normal chromosome 9 Type A and B
[33] 61 yo/F 46,XX,add(9)(q34) ETV6 signal on derivative chromosome 9 N/A
[21] 79 yo/M 46,XY ABL1 signal on apparently normal chromosome 12 N/A
[22] 36 yo/M 46,XY,t(9;12)(q34;p13) Extra ABL1 signal (interphase FISH) Type B
[1] 46/F 46,XY,t(9;12)(q34;p13)[10] Extra ETV6 and ABL1 signals (interphase FISH) Type B
[5] N/A Complex rearrangement involving
chromosomes 6, 9, and 12
Suggestive of ETV6-ABL1 fusion N/A
[34] 31 yo/M 46,XY,der(9)t(9;12)(q34;p13), del(12)(p13)[1] ETV6 signal on derivative 9 Type A and B
Age/sex of patient, karyotype, salient FISH findings, and type of ETV6-ABL1 fusion transcript detected are provided
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rearrangements involving a third chromosome - Golub et
al. reported a case of AML (M6) with a t(9;12;14)
(q34;p13;q22) without additional FISH studies, and La
Starza et al. reported a case of AML (M1) with a
t(8;12)(p21;p13) that showed colocalization of 5’ ETV6
and 3’ ABL1 signals on 8p21 by FISH [3, 4]. The two
remaining cases showed normal karyotypes by conven-
tional cytogenetics, but showed 3’ ABL1 signals on 12p
[13, 14]. Among all of these cases, reported secondary ab-
normalities observed included gains of chromosomes 8, 9,
11, 12, 14, 17, and 19, as well as a t(1;22) [4, 14].
The ETV6-ABL1 fusion includes a helix loop helix
(HLH) domain of ETV6 and tyrosine kinase domain of
ABL1, and each domain is necessary for constitutive
phosphorylation to occur [4]. Millon et al. found that
mice transplanted with ETV6-ABL1-positive hematopoietic
stem cells developed CML-like myeloproliferative disease,
and that the TEL pointed homology oligomerization
domain was essential to ETV6-ABL1-driven leukemo-
genesis [15]. It is well known that the ABL1 kinase has
altered catalytic specificity in human leukemia. Co-
immunoprecipitation studies show that the ETV6-ABL1
fusion protein tends to form complexes with CrkL in
Ba/F3 cells, and this interaction phosphorylates CrkL
and possibly CrkII [16]. However, it is known that the
in vitro studies tend to have a wider range of sub-
strates than the cellular forms [16]. Further analysis of
Crk and CrkL adaptor proteins show that they play an
essential role in integrating signals from a wide variety
of sources such as apoptotic cells, extracellular matrix
molecules, and growth factors, and there is mounting
evidence to indicate that these proteins are associated
with human diseases including susceptibility to patho-
gens and cancer [17].
ETV6 along with five other genes, BCR, ZMIZ, EML,
and Nup21 form chimeric transcripts with ABL1. There
must be a joining of the 3’ sequence of ABL1 with the 5’
end of the partner genes, and most of these genes are as-
sociated with a wide spectrum hematologic malignan-
cies. Despite this heterogeneity, there is likely a common
pluripotent stem cell that gives rise to similar transduc-
tion pathways and transforming activity [1]. Due to diag-
nostic, prognostic, and treatment-related implications,
these cases further underscore the use of FISH along
with routine chromosome analysis to properly charac-
terize rare, albeit clinically significant fusion genes.
Eosinophilia is a recurrent morphologic finding in
ETV6-ABL1-positive myeloid malignancies [4]. Of the
five known AML ETV6-ABL1 positive cases, three out
of the five were reported to have an increased abnormal
eosinophil count, consistent with the findings in the
present case. Another finding common to most of the
patients was leukocytosis and out of those three cases,
two had both leukocytosis and eosinophilia [3, 4, 13, 14].
Each patient was treated with chemotherapy including,
cytosine-arabinoside, idarubicin, etoposide, mitoxan-
trone, and cytarabine. The two patients treated with
imatinib responded transiently with resolved fluid reten-
tion, eosinophilia, and leukocytosis; however, full remis-
sion was not achieved [14]. There was only one patient
who achieved full cytogenetic and hematological remis-
sion 20 months after undergoing allogeneic hematopoietic
stem cell transplantation, which suggests its effectiveness
in the treatment of ETV6-ABL1-positive AML patients
with eosinophilia and leukocytosis [4].
Although there is limited information about the patho-
genesis of myeloid neoplasms positive for ETV6-ABL1,
chronic myeloid leukemia (CML) positive for BCR-ABL1
has been well studied and the molecular mechanisms of
leukemogenesis and courses of clinical management are
established. Tyrosine kinase inhibitors (TKI) such as
imatinib are effective agents for inhibiting the constitu-
tively activated BCR-ABL1 tyrosine kinase in CML [18].
Similarly, ETV6-ABL1 is also known to constitutively ac-
tivate the ABL1 tyrosine kinase, leading to cell cycle de-
regulation and leukemogenesis [19]. Due to the similar
molecular pathogenesis of BCR-ABL1 and ETV6-ABL1
driven leukemogenesis, TKIs have also been considered
in the treatment of patients bearing the ETV6-ABL1 fu-
sion. Six out of eleven CML patients positive for ETV6-
ABL1 reported in the literature were treated with imatinib:
three patients showed a transient favorable response
followed by relapse, one patient showed significantly de-
creased levels of leukemic clones, and two patients treated
with 400 mg/day during the chronic phase achieved
complete remission [1, 6, 18, 20–22]. Of the three that re-
lapsed, Gancheva et al. reported a case in which the pa-
tient was administered an additional TKI, nilotinib, and
the patient was able to sustain a positive response follow-
ing the relapse [1]. Perna et al. did further analysis on
another patient who achieved complete remission post-
treatment which showed that the ETV6-ABL1 transcript
became undetectable, the white blood count normalized,
and expression of C-MYC, ID1, BCL-XL, and NUP-98 had
decreased significantly [22]. All in all, the molecular tar-
gets of ETV6-ABL1 and BCR-ABL1 have significant over-
laps that warrant further investigation to elucidate the
effectiveness of TKIs on ETV6-ABL1 positive hematologic
malignancies.
All in all, this is the sixth reported case of AML bear-
ing the ETV6-ABL1 fusion gene and provides additional
insight into the pathogenesis of this subset of malignan-
cies. It is particularly important to utilize complimentary
cytogenetic methodologies - namely conventional cyto-
genetics and FISH - in order to elucidate cryptic abnor-
malities, which occur more frequently in this context,
and to properly characterize karyotypic changes. Add-
itionally, screening using RT-PCR as well as other
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methodologies has proven useful when cytogenetic ana-
lysis is unavailable or yields negative results and in the
context of broad molecular screening to identify previ-
ously unreported cases. Finally, the consideration of
tyrosine kinase inhibitors, particularly second-generation
ones, in the treatment of ETV6-ABL1-positive hemato-
logical malignancies has shown varying responses, and
further investigation of its utility and clinical efficacy is
warranted.
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